The aim of this study is whether to predict the delayed response click here in naive CHB patients, particularly in those with partial virological response (PVR). Methods In s single center cohort study,

we investigated 425 patients treated with entecavir monotherapy. PVR was defined as the detectable HBV DNA after 48 weeks. Virological response (VR) was defined as HBV DNA <20 IU/mL. Quantitative serum levels of HBsAg, HBeAg and HBV DNA were serially assessed at baseline and 3-month intervals. Results Virological response was achieved in 91%, 95%, 93% and 93% of patients at weeks 48, 96, 144, and 192 respectively. One hundred one patients out of 291 patients (65.3%) who were treated over one year showed PVR to 48 weeks of entecavir treatment. The patients with PVR from baseline to weeks 12, 24, 36 and 48 had more HBeAg positivity and higher levels of HBsAg, HBeAg, and HBV DNA than those with VR (P < 0.005). During prolonged entecavir monotherpy in 101 patients with PVR, 32/71 (45.1%) and 31/50 (62%) and 15/21 (71.4%) achieved virological response at weeks 96, 144 and 192, and none of them developed entecavir resistance. In the patients with PVR at week 48 for the predicting VR at week 96, HBsAg <3.5 log IU/ml at week 48 showed 73.9% of sensitivity and 70.0% of specificity (AUROC 0.707, P = 0.008) and HBV DNA < 343 IU/ml at week 48 showed 64.1% of sensitivity and PD-0332991 cost 90.6% of specificity (AUROC 0.811,

P = 0.000). Conclusions The majority of patients with PVR to 48 weeks of entecavir therapy achieved VR during the prolonged monotherpy. The patients with PVR had the higher levels of HBsAg, HBeAg, and HBV DNA at baseline and on-treatment period for 48 weeks than those with VR. In addition, the patients who showed HBsAg <3.5 log IU/ml or HBV DNA <

343 IU/ml at week 48 were likely to achieve the VR at the short term, week 96. Disclosures: The following people have nothing to disclose: Jung Hyun Kwon, Jeong Won Jang Background: Nucleotide analogues have been implicated in decreasing the estimated glomerular filtration rate (eGFR). Observational data suggest that telbivudine (LdT) may improve eGFR in compensated CHB 上海皓元 patients. This retrospective study evaluates the changes in eGFR during long-term telbivudine therapy in patients with advanced fibrosis and cirrhosis. Methods: eGFR was assessed in GLOBE study patients (CLDT600A2302) with an Ishak Fibrosis score of 3-6 (IF >3-6) at baseline, using MDRD formula, and evaluated as absolute changes and percentage changes from baseline to 1 04 weeks. Analyses of patients grouped by baseline eGFR values were performed. Response to LdT and lamivudine (LAM) was assessed by HBV DNA <300 cp/ml (undetectability) and by HBeAg loss or seroconversion at Week 104. A multivariate analysis was performed to assess if baseline characteristics and predictors of efficacy outcomes at Week 104 influence eGFR shifts.